[go: up one dir, main page]

PL376926A1 - Nowe analogi 2',5'-oligoadenylanowe - Google Patents

Nowe analogi 2',5'-oligoadenylanowe

Info

Publication number
PL376926A1
PL376926A1 PL376926A PL37692603A PL376926A1 PL 376926 A1 PL376926 A1 PL 376926A1 PL 376926 A PL376926 A PL 376926A PL 37692603 A PL37692603 A PL 37692603A PL 376926 A1 PL376926 A1 PL 376926A1
Authority
PL
Poland
Prior art keywords
novel
acid analogues
oligoadenylic acid
oligoadenylic
analogues
Prior art date
Application number
PL376926A
Other languages
English (en)
Other versions
PL211566B1 (pl
Inventor
Makota Koizumi
Koji Morita
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32321740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL376926(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of PL376926A1 publication Critical patent/PL376926A1/pl
Publication of PL211566B1 publication Critical patent/PL211566B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL376926A 2002-11-19 2003-11-19 Analog 2',5'-oligoadenylanowy, kompozycja farmaceutyczna zawierająca analog 2',5'-oligoadenylanowy oraz zastosowanie analogu 2',5'-oligoadenylanowego PL211566B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002334731 2002-11-19

Publications (2)

Publication Number Publication Date
PL376926A1 true PL376926A1 (pl) 2006-01-09
PL211566B1 PL211566B1 (pl) 2012-05-31

Family

ID=32321740

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376926A PL211566B1 (pl) 2002-11-19 2003-11-19 Analog 2',5'-oligoadenylanowy, kompozycja farmaceutyczna zawierająca analog 2',5'-oligoadenylanowy oraz zastosowanie analogu 2',5'-oligoadenylanowego

Country Status (17)

Country Link
US (2) US7651999B2 (pl)
EP (1) EP1568704A4 (pl)
KR (1) KR101117998B1 (pl)
CN (1) CN1738829B (pl)
AU (1) AU2003284578B2 (pl)
BR (1) BR0316431A (pl)
CA (1) CA2506581C (pl)
CO (1) CO5690648A2 (pl)
IL (1) IL168475A (pl)
MX (1) MXPA05005321A (pl)
NO (1) NO20052975L (pl)
NZ (1) NZ539979A (pl)
PL (1) PL211566B1 (pl)
RU (1) RU2311422C2 (pl)
TW (1) TWI347948B (pl)
WO (1) WO2004046161A1 (pl)
ZA (1) ZA200504017B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
TWI347948B (en) * 2002-11-19 2011-09-01 Sankyo Co Novel 2',5'-oligoadenylic acid compositions
US20050106101A1 (en) * 2003-10-31 2005-05-19 Ajay Purohit Novel chemical agents comprising an adenosine moiety or an adenosine analog moiety and an imaging moiety and methods of their use
KR20110044337A (ko) * 2005-05-18 2011-04-28 미쓰이 가가쿠 가부시키가이샤 올레핀 중합용 촉매, 올레핀 중합체의 제조방법, 프로필렌계 공중합체의 제조방법, 프로필렌 중합체, 프로필렌계 중합체 조성물 및 이들의 용도
EP2121719A2 (en) * 2007-01-31 2009-11-25 Alios Biopharma, Inc. 2-5a derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
WO2009086201A1 (en) * 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
US20100009451A1 (en) * 2008-05-30 2010-01-14 Sigma Aldrich Company Compositions and methods for specifically silencing a target nucleic acid
CA2832972C (en) 2011-04-13 2019-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
TW201402594A (zh) * 2012-06-18 2014-01-16 Daiichi Sankyo Co Ltd 核苷類似物的製造中間體及其製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927055T2 (de) * 1988-06-09 1997-04-10 Temple University Of The Commonwealth System Of Higher Education, Philadelphia, Pa. 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
RU2131436C1 (ru) * 1990-09-13 1999-06-10 Санофи Резистентные к нуклеазе олигонуклеозиды, способ их получения и резистентный к нуклеазе нуклеозидный димер
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
RU2233844C2 (ru) * 1999-02-12 2004-08-10 Санкио Компани Лимитед Новые нуклеозидные и олигонуклеотидные аналоги
WO2001022970A1 (en) * 1999-09-29 2001-04-05 The Cleveland Clinic Foundation Therapy with 2-5a and interferon
JP4245837B2 (ja) * 2000-12-21 2009-04-02 第一三共株式会社 ２’，５’−オリゴアデニル酸類縁体
TWI347948B (en) * 2002-11-19 2011-09-01 Sankyo Co Novel 2',5'-oligoadenylic acid compositions

Also Published As

Publication number Publication date
NO20052975D0 (no) 2005-06-17
US20050261235A1 (en) 2005-11-24
KR20050083891A (ko) 2005-08-26
US20100035976A1 (en) 2010-02-11
TWI347948B (en) 2011-09-01
CA2506581A1 (en) 2004-06-03
NO20052975L (no) 2005-08-18
CN1738829B (zh) 2012-11-28
EP1568704A4 (en) 2009-12-02
RU2005115129A (ru) 2006-02-27
ZA200504017B (en) 2006-02-22
RU2311422C2 (ru) 2007-11-27
CN1738829A (zh) 2006-02-22
US7651999B2 (en) 2010-01-26
AU2003284578A1 (en) 2004-06-15
WO2004046161A1 (ja) 2004-06-03
NZ539979A (en) 2007-05-31
EP1568704A1 (en) 2005-08-31
TW200416224A (en) 2004-09-01
CO5690648A2 (es) 2006-10-31
IL168475A (en) 2010-05-31
AU2003284578B2 (en) 2007-07-05
PL211566B1 (pl) 2012-05-31
KR101117998B1 (ko) 2012-04-12
BR0316431A (pt) 2005-10-11
US7994152B2 (en) 2011-08-09
CA2506581C (en) 2013-05-28
MXPA05005321A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
SI1555267T1 (sl) 2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI
IL164966A0 (en) 3?-Ä2Z)-Ä1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylideneÜhydrazinoÜ-2'-hydroxy-Ä1,1'-biphenylÜ-3-carboxylic acid bis-(monoethanolamine)
IL163817A0 (en) 2,4-Diaminopyrimidine
GB0128526D0 (en) Nucleotide analogues
PL377187A1 (pl) Związki ze skondensowanym pierścieniem 1,3-dihydroimidazolowym
IL166710A0 (en) Process for the preparation of 4-ÄÄ4-ÄÄ-(2-cyanoethenyl)2,6-dimethylphenylÜaminoÜ-2-pyrimidinylÜaminoÜbenzonitrile
MXPA03007595A (es) Analogos de acido ascorbico para metalorradiofarmaceuticos.
IL149005A0 (en) Hexahydrofuro-2', 3-bifuran-3-yl-n-{3'(1, 3-benzodioxol-5-ylsulfonyl) (isobutyl) amino-1-benzyl-2-hydroxypropyl} carbamate as restroviral protease inhibitor
AU2003277021A8 (en) Glycosylceramide analogues
GB0206189D0 (en) None available at present time
PL376926A1 (pl) Nowe analogi 2',5'-oligoadenylanowe
EP1548026A4 (en) NEW DEPSIPEPTID CONNECTION
GB0129988D0 (en) Imidazolidineacetic acid derivatives
PL373883A1 (pl) 2,5-dipodstawiony kwas 3-merkaptopentanowy
MXPA03009091A (es) Amidas novedosas del acido n-p-propargiloxifenetil-tioacetico.
PL366978A1 (pl) Analogi kwasu hydroksytłuszczowosulfonowego
ZA200303991B (en) "Polymerization".
AU2003257651A1 (en) 4'-thionucleotide
GB0202087D0 (en) Non-drain 'T' connector
AU2003275360A8 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
IL162880A0 (en) Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyk) dodecanoic acid
GB2386580B (en) The bricky's mate
GB2391856B (en) "Font"
EP1536008A4 (en) 2 ', 5'-OLIGOADENYLATE PHOSPHODIESTERASE
GB0224496D0 (en) I'll jump it

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20131119